Document is current
Any future updates will be listed below
-
Authors
Li, Tian-Tian
Yao, Wei-Qi
Dong, Hai-Bo
Wang, Ze-Rui
Zhang, Zi-Ying
Yuan, Meng-Qi
Shi, Lei
Wang, Fu-Sheng https://orcid.org/0000-0002-8043-6685
-
Funding
Funding for this research was provided by:
The National Key Research and Development Program of China (2022YFA1105604, 2020YFC0860900, 2017YFA0105700)
- License Information
-
More Information
Article History
Received: 20 April 2023
Accepted: 16 November 2023
First Online: 10 December 2023
Declarations
:
: IRB approval was submitted and granted for this study. (1) Title of the approved project: “Treatment with human umbilical cord-derived mesenchymal stem cells for severe corona virus disease 2019 (COVID-19).” (2) Name of the institutional approval committee or unit: the Ethics Committee of the Fifth Medical Center, Chinese PLA General Hospital. (3) Approval number: 2020-013-D. (4) Date of approval: February 24, 2020.
: Not applicable.
: W.Q.Y. is the current employee of Wuhan Optics Valley Zhongyuan Pharmaceutical Co., Ltd. H.B.D. is the current employee of Wuhan Optics Valley Vcanbio Cell and Gene Technology Co. The authors declare no potential conflict of interest.
